C12N 2720/12171
Demonstrated in vivo effect
C12N2720/12171 (Demonstrated in vivo effect) appears on 5 US grants and 5 published applications in this corpus.
Search patents in C12N- Granted patents
- 5
- Published applications
- 5
- Assignees
- 7
- Inventors
- 14
- Latest grant
- 7 Feb 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 1 | 1 |
| 2019 | 0 | 1 |
| 2020 | 1 | 0 |
| 2021 | 1 | 1 |
| 2022 | 1 | 0 |
| 2023 | 1 | 0 |
By publication year.
Recent patents
- Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine7 Feb 2023US 11,571,471 B2Bavarian Nordic A/S
- Epizootic hemorrhagic disease virus—tel aviv university (EHDV-TAU)—oncolytic virus for treating cancer1 Nov 2022US 11,484,558 B2Ramot at Tel-Aviv University Ltd.
- Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine5 Jan 2021US 10,881,725 B2Bavarian Nordic A/S
- Reassortant BTV and AHSV vaccines13 Oct 2020US 10,801,039 B2Boehringer Ingelheim Animal Health USA Inc.
- Vaccines for diseases caused by viruses of the family of reoviridae20 Mar 2018US 9,919,044 B2Stichting Wageningen Research
- Recombinant Modified Vaccinia Virus Ankara (MVA) Equine Encephalitis Virus Vaccine8 Jul 2021US 2021/0205439 A1Bavarian Nordic A/S
- Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine7 Feb 2019US 2019/0038739 A1Bavarian Nordic A/S
- Epizootic hemorrhagic disease virus - tel aviv university (ehdv-tau) - oncolytic virus for treating cancer27 Dec 2018US 2018/0369302 A1Ramot at Tel-Aviv University Ltd.
- Vaccines for diseases caused by viruses of the family of reoviridae9 Jun 2016US 2016/0158342 A1Stichting Dienst Landbouwkundig Onderzoek
- Reassortant btv and ahsv vaccines19 Dec 2013US 2013/0337010 A1Merial Limited
Most cited
By later US patents